Savient Pharmaceuticals Inc

Savient Pharmaceuticals — Investor Presentation (September 2005)

35 slides from Savient Pharmaceuticals's investor presentation, Sep 7, 2005

  1. Slide 1: Savient Redefined

    Savient Redefined Christopher Clement President and Chief Executive Officer NASDAQ: SVNT

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this report regarding the Company’s strategy, expected future financial positio

  3. Slide 3: Agenda

    Agenda Savient Overview Executing Our Strategy Milestones Summary

  4. Slide 4: Long Heritage

    Long Heritage Bio-Technology General Corporation 1980 - 2002 2003 Name Change to

  5. Slide 5: Time for Change

    Time for Change Need for clear strategic focus Thorough internal review of existing business uncovered: – Potential generic introduction for largest-selling brand – Oxandrin ® – Dwindling sources of funds – Lack of other near-term commercial opportunities – Unsuccessful biologics research – Languish

  6. Slide 6: Oxandrin: Today

    Oxandrin ® : Today Anticipating generic competition – Citizens petition filed February 2004 Maximizing sales and marketing efforts until market dynamics change – New leadership – Terminated CSO – Revitalized/refocused own field force

  7. Slide 7: Focused Strategic Value Driven

    Focused Strategic Value Driven Transitioning to the New Savient

  8. Slide 8: Our Strategy

    Savient Pharmaceuticals, Inc. Unlocking Shareholder Value EXPANDING Our Portfolio EXTENDING Our Reach ADVANCING Our Pipeline Our Strategy Rosemont Oral Liquids Puricase ® Business Development

  9. Slide 9: New Leadership

    New Leadership Zeb Horowitz, MD SVP, CMO 25 Years pharmaceutical/medical research 13 Years industry experience – Procter & Gamble and Novartis Assistant/Associate Professor of Medicine – NYU & University of Cincinnati Christopher Clement President and CEO 25 Years global pharmaceutical management Ep

  10. Slide 10: Transition to Specialty Pharma

    Savient Pharmaceuticals, Inc. Emerging Rheumatology Franchise Rosemont Oral Liquids Biologics Mfg. Business Transition to Specialty Pharma X $80 Million Cash

  11. Slide 11: Executing Our Strategy

    Savient Pharmaceuticals, Inc. Unlocking Shareholder Value EXPANDING Our Portfolio EXTENDING Our Reach ADVANCING Our Pipeline Executing Our Strategy Rosemont Oral Liquids Puricase ® Business Development

  12. Slide 12: Rosemont Pharmaceuticals, Ltd.

    Rosemont Pharmaceuticals, Ltd. Extending Our Reach

  13. Slide 13: Rosemont Overview

    Rosemont Overview Wholly-owned U.K. subsidiary Acquired from Akzo Nobel in 2003 Liquid formulations of off-patent prescription pharmaceuticals (solid dosage alternative) Uniquely positioned, targeting the elderly/geriatric population High margin business – Continued double-digit growth Extending geo

  14. Slide 14: Extending Our Reach

    Extending Our Reach Numerous Opportunities For Growth Rosemont Pharmaceuticals, Ltd. U.S. Soltamox Potential for other ANDAs/NDAs Obtain U.S. marketing and distribution partner U.K. Pediatrics Proprietary products GP Market Continental Europe Other products/countries

  15. Slide 15: Executing Our Strategy

    Savient Pharmaceuticals, Inc. Unlocking Shareholder Value EXPANDING Our Portfolio EXTENDING Our Reach ADVANCING Our Pipeline Executing Our Strategy Rosemont Oral Liquids Puricase ® Business Development

  16. Slide 16: Unmet Medical Need: Gout

    Unmet Medical Need: Gout Painful rheumatic disease Symptomatic hyperuricemia Results from over-production or under-excretion of uric acid Deposits crystals of uric acid in connective tissues and/or joint spaces – Gouty arthritis – Gout tophi – Gout flares – Gout-related kidney disease What is Gout?

  17. Slide 17: Refractory Gout

    Refractory Gout Painful / debilitating inflammation Destructive arthritis Development of tophi Renal complications Refractory Gout is a Serious Unmet Medical Condition With Significant Clinical Consequences

  18. Slide 18: Illustration of Gout Tophi

    Source: ACR Illustration of Gout Tophi

  19. Slide 19: Puricase Overview

    Puricase ® Overview PEG technology MPV and Duke Exclusive license to trademark from MPV Combined low double-digit royalties Ownership: Completed: Phase 2 Initiating Phase 3: 1Q06 Status: Potential to be first effective therapy to reverse course of the disease Differentiation: Estimates vary widely 2

  20. Slide 20: Phase II Study Design

    Puricase ® Randomized, double-blind, multi-center, parallel groups Two dose levels with two dose regimens: – 4 mg and 8 mg every 2 weeks – 8 mg and 12 mg every 4 weeks Twelve week exposure Sample size: ~10 per treatment group 9 Sites in U.S. Phase II Study Design

  21. Slide 21: Phase II Study Efficacy

    Puricase ® Phase II Study Efficacy Maximum % decrease in PUA from baseline within the first 24 hours (p<.0001) –93% 4 weeks 12 mg (p<.0001) –87% 4 weeks 8 mg (p<.0001) –94% 2 weeks 8 mg (p=.0002) –72% 2 weeks 4 mg (p value) Percent Decrease Arm Study % Decrease in PUA from baseline over the 12-week

  22. Slide 22: Phase II Study Efficacy (cont'd)

    Puricase ® No increase in gout flare frequency with normalization of plasma uric acid Anecdotal reports from patients and investigators – Eradication of gout tophi – Improvement in joint function – Improvement in sense of well being Phase II Study Efficacy (cont’d.)

  23. Slide 23: Phase II Study Safety

    Puricase ® General – No medically important signal of drug-related AEs or laboratory abnormalities Gout flares – No increase in frequency over time with normalization of uric acid Infusion reactions typical for biologicals Allergy – No clearly allergic manifestations Phase II Study Safety

  24. Slide 24: Proposed Phase III Program

    Puricase ® Working with FDA to finalize Program designed to evaluate: – Effectiveness in the control of uric acid – Effectiveness in multiple clinical outcomes Elected to submit Special Protocol Assessment (SPA) Proposed Phase III Program

  25. Slide 25: Puricase Summary

    Puricase ® Development program to date strong basis for full development and registration Key efficacy endpoints – Control of uric acid (determines approvability) – Improvement in clinical outcomes Correlations between suppression of PUA and clinical outcomes will be evaluated in this study Summary

  26. Slide 26: Refining Our Therapeutic Focus

    Refining Our Therapeutic Focus An Emerging Rheumatology Franchise

  27. Slide 27: Why Rheumatology?

    Growing Market for Novel Technologies A “Resource Manageable” Market Puricase Will be Targeted to Rheumatologists Unique Positioning for Savient Rheumatology is an Area of Strategic Long-Term Focus Why Rheumatology?

  28. Slide 28: Building our Rheumatology Franchise

    In-licensing Co-promotion Euflexxa ™ Puricase ® Building our Rheumatology Franchise Opportunities in Rheumatology Time 2005 2008

  29. Slide 29: Euflexxa Overview

    Euflexxa ™ Overview Approximately $500 million Synvisc: 61% market 2004 WW HA Market: 2004 Market Leader: Only non-avian derived HA Head-to-head data with Synvisc Differentiation: Approved Scheduled launch 4Q 2005 Status: July 2005 co-promotion agreement with Ferring (product owner) to market to U.S

  30. Slide 30: Our Strategy

    Savient Pharmaceuticals, Inc. Unlocking Shareholder Value EXPANDING Our Portfolio EXTENDING Our Reach ADVANCING Our Pipeline Our Strategy Rosemont Oral Liquids Puricase ® Business Development

  31. Slide 31: Expanding our Product Portfolio

    Expanding our Product Portfolio Utilize experienced, focused business development team Maximize competitive advantages – Fast and flexible management team – Strong balance sheet Expedite opportunity assessment process – Proactive and disciplined Seek savvy partnering agreements Isolate and pursue st

  32. Slide 32: Future Milestones

    Future Milestones Delivering Results

  33. Slide 33: 2005 – 2006 Milestones

    2005 – 2006 Milestones Approval of Soltamox ® Co-promotion with Ferring for Euflexxa ™ in U.S. Announcement of strategic commercialization partner for Soltamox ® Agreement with FDA on SPA for Puricase ® Phase 3 Development Program Contract with development and commercialization partner for Puricase

  34. Slide 34: The New Savient

    The New Savient Extending Our Reach Executing New Strategy Advancing Our Pipeline Expanding Our Portfolio Financially Stable Delivering Results

  35. Slide 35: Savient Redefined

    Savient Redefined

Savient Pharmaceuticals — Investor Presentation (September 2005) on 6ix